# AVALO THERAPEUTICS INC (AVTX)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/AVTX/

- Reporting holders: 4
- Reported value: $4.1K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $2.9K | 189 | 0.0% | 1 |
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $782 | 51 | 0.0% | 1 |
| [CoreCap Advisors, LLC](https://holderbook.com/funds/1902501-corecap-advisors-llc/) | $199 | 13 | 0.0% | 1 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $184 | 12 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 4 | $4.1K |
| Q2 2026 | 131 | $1.4B |
| Q1 2026 | 103 | $518.2M |
| Q4 2025 | 86 | $370.5M |
| Q3 2025 | 65 | $196.8M |
| Q2 2025 | 36 | $39.2M |
| Q1 2025 | 33 | $66.1M |
| Q4 2024 | 33 | $56.0M |
| Q3 2024 | 28 | $63.2M |
| Q2 2024 | 21 | $9.6M |
| Q1 2024 | 18 | $1.9M |
| Q4 2023 | 12 | $209.8K |